poisar

Stocks · News reference

Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GNLX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate

    Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same

    GNLX